Navigation Links
European Regulatory Agency Accepts Cell Therapeutics, Inc.'s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
Date:4/1/2008

SEATTLE, April 2, 2008 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTA) today announced that the European Medicines Agency (EMEA) has accepted for review CTI's Marketing Authorization Application (MAA) for XYOTAX(TM) (paclitaxel poliglumex, CT-2103) for first-line treatment of patients with non-small cell lung cancer (NSCLC) with ECOG (Eastern Cooperative Oncology Group) performance status 2 (PS2). CTI submitted the MAA at the beginning of March. The validation of the MAA for XYOTAX initiates the marketing approval review process, which generally takes 15 to 18 months. The application is based on advice from the Scientific Advice Working Party, or SAWP, at the EMEA. The EMEA agreed that switching the primary endpoint from superiority to non-inferiority is feasible if the retrospective justification provided in the marketing application is adequate. The discussions with the SAWP focused on using the STELLAR 4 study as primary evidence of non-inferiority and the STELLAR 3 study as supportive of the MAA.

In the STELLAR 4 trial, single-agent XYOTAX resulted in comparable survival to gemcitabine or vinorelbine in first-line patients and, with the exception of neuropathy known to be associated with taxane therapy, demonstrated significant reduction in several clinically meaningful toxicities, such as severe neutropenia and infection, and in the requirement for transfusions and use of hematopoietic growth factor support. In addition to improved tolerability, XYOTAX offered more convenient administration compared to currently used treatments and a reduction in overall utilization of medical resources compared to gemcitabine or vinorelbine.

"CTI looks forward to working with the EMEA as it begins the review
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
2. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
3. European Experts Recommend Pregnant and Nursing Women Take More DHA - Every Day
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
6. Threshold Pharmaceuticals Announces Two Presentations on Glufosfamide at the 2007 European Cancer Conference (ECCO)
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Life Recovery Systems Receives European CE Mark Approval for Its ThermoSuit(R) System
9. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
10. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
11. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... CHICAGO , June 19, 2013 The Physician-Patient ... reduce alarm fatigue. The need to urgently address ... in its Sentinel Event Alert #50 , "Medical device alarm ... Alert database, between January 2008 and June 2012, there were ... 80 resulted in death (82%) , 13 resulted in ...
(Date:6/19/2013)... 19, 2013  Finesse Solutions, Inc, a manufacturer ... process applications, announced the launch of its new ... culture and fermentation.  The 3L glass vessels are ... Finesse bioreactors and are designed to optimize yield ... fully compatible with all Finesse G3Lab controllers, and ...
(Date:6/19/2013)... , June 19, 2013   Voices Against ... finding a cure for brain cancer, today announced that ... grant to support the clinical investigation of Toca 511 ... high grade glioma brain cancer (Grade 3 or Grade ... novel treatments for advanced cancer, with an initial focus ...
Breaking Medicine Technology:Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 2Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 3Finesse Solutions Launches Next Generation SmartGlass 3L Bioreactors for Cell Culture and Fermentation 2Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 2Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 3
... Remedi SeniorCare®, which is among the nation,s largest ... (LTC) pharmacy industry with the Paxit™ med-pass system, ... by fully automated centralized proprietary dispensing technology. Remedi ... Maryland and the Washington, D.C. area, where its ...
... MSHL ), an oncology company focused on the ... that it will host its Annual Meeting of Stockholders on ... of Morgan, Lewis & Bockius LLP, located at 101 Park ... on certain matters, including the approval of the transactions contemplated ...
Cached Medicine Technology:Remedi SeniorCare Expands Distribution of the Paxit™ Med-Pass Solution, the New Standard in Medication Administration 2Remedi SeniorCare Expands Distribution of the Paxit™ Med-Pass Solution, the New Standard in Medication Administration 3Remedi SeniorCare Expands Distribution of the Paxit™ Med-Pass Solution, the New Standard in Medication Administration 4Marshall Edwards to Host Annual Meeting of Stockholders 2Marshall Edwards to Host Annual Meeting of Stockholders 3
(Date:6/19/2013)... 2013 Author Byron Oberst draws on his ... explanation of how the body’s defense mechanisms work in his ... Health Pirates ” (published by Trafford Publishing). , Ideal for ... tells the story of Bobbie, a little boy who wakes ... mother takes him to visit Doctor Getwell, who prescribes antibiotics ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 Daily Gossip issued ... jump training method will be published on their website ... of the article to inform readers about the information they ... made by reporters working at Daily Gossip, the article is ... . , Hiller has understood during the vast research ...
(Date:6/19/2013)... June 19, 2013 PrettySkin4Less announces it ... skin serums by top skin care manufacturer EMINENCE ... concentrations of vitamins, minerals and active organic ingredients to ... so many other beauty products offer. For this reason ... up. , "I like products that do what ...
(Date:6/19/2013)... Salt Lake City, UT (PRWEB) June 19, 2013 ... wellness companies : , In July 2013, Orriant ... optimize their participation rates, and maintain compliance with ... implemented allowing employees to receive wellness incentives if ... Orriant has announced they have been compliant with ...
(Date:6/19/2013)... 19, 2013 As Januvia lawsuit ... to mount in courts throughout the U.S., Bernstein Liebhard ... (FDA) recently held a meeting to discuss the safety ... mimetics. According to a June 12th report from ... makers of Januvia and similar drugs, following a recent ...
Breaking Medicine News(10 mins):Health News:New Book Shows Children How the Body Fights Germs 2Health News:The Jump Manual Review: Reveals Hiller’s Method of Vertical Jump Training 2Health News:PrettySkin4Less Launches New Innovative Skin Serums with Active Organic Ingredients to World Wide Consumer Base 2Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 2Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 3Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 2Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 3
... for patients in just the first six months after they ... in Canada, according to a study presented today at the ... Ischemic Stroke (BURST) study found that the direct and indirect ... in the six-month period following a new stroke. There are ...
... June 8, 2010The new Center for Medicare and Medicaid ... and implementing payment initiatives, continuously monitor their impact, and ... in order to realize the potential for improved health ... Health Affairs article by Commonwealth Fund researchers. ...
... (June 7, 2010) Researchers from the BC Centre ... British Columbia today released a comprehensive study revealing that ... would create significant benefits for individuals infected with HIV ... modeling study, published in the research journal PLoS ...
... at Purdue University have developed a potential new tool ... and crime-scene forensics. The technique uses a combination ... tiny particles, such as bacteria, viruses and DNA, which ... either light or electric fields separately are able to ...
... target cancerous plasma cells appears promising in treating multiple myeloma, ... at the drug elotuzumab, an antibody which is designed to ... cells. The antibody has the potential to attach to malignant ... early stage trial combined elotuzumab with bortezomib, or Velcade, one ...
... common in younger men, and it,s often more aggressive in ... of Michigan Comprehensive Cancer Center has found that a series ... cancer. Researchers believe that genetics and traditional screening methods ... cancer in younger men. "This is a potential ...
Cached Medicine News:Health News:Cost of caring for stroke patients double that of earlier estimates 2Health News:Cost of caring for stroke patients double that of earlier estimates 3Health News:Center for Medicare and Medicaid Innovation must implement payment reforms rapidly 2Health News:Center for Medicare and Medicaid Innovation must implement payment reforms rapidly 3Health News:Updated HIV therapy guidelines would reduce risk of transmission, save lives, billions in costs 2Health News:Updated HIV therapy guidelines would reduce risk of transmission, save lives, billions in costs 3Health News:New method manipulates particles for sensors, crime scene testing 2Health News:New method manipulates particles for sensors, crime scene testing 3
... CVA for CELL-DYN are assayed linearity control ... and to verify patient reportable range of ... also measure the linear performance of the ... have customized ranges appropriate for each instrument ...
The technology in the LATITUDE system allows your doctor to get the same data from your device whether you are at home or in your doctor's office. This information transfer happens automatically....
... Proprietary EX.P.R.T. Release ... jumping,, No stent shortening,, Unique anatomically ... in the carotid bifurcation,, 0.014 Rapid ... crossing profile and flexible atraumatic tip,, ...
... Para 5X is a whole blood ... Pentra 60C+, 80 and 120, and the ... product offers a unique white cell differential, ... the algorithms on the systems. The product ...
Medicine Products: